fozivudine tidoxil: a thioether lipid-zidovudine (ZDV) conjugate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 64140 |
| CHEMBL ID | 3989603 |
| SCHEMBL ID | 14032206 |
| MeSH ID | M0363808 |
| Synonym |
|---|
| fozivudine tidoxil |
| [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate |
| 141790-23-0 |
| (2rs)-2-(decyloxy)-3-(dodecylthio)propyl hydrogen 3'-azido-3'-deoxy-5'-thymidylate |
| foxivudine tidoxil |
| unii-687805287f |
| bm 21.1290 |
| 687805287f , |
| fozivudine tidoxil [inn] |
| bm 21-1290 |
| 5'-thymidylic acid, 3'-azido-3'-deoxy-, mono(2-(decyloxy)-3-(dodecylthio)propyl) ester |
| fozivudine |
| phosphoric acid (2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl ester 2-decyloxy-3-dodecylsulfanyl-propyl ester |
| [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methyl (2-decoxy-3-dodecylsulfanyl-propyl) hydrogen phosphate |
| bm-21.1290 |
| bm-211290 |
| hdp 990002 |
| hdp-990002 |
| fozivudine tidoxil [who-dd] |
| SCHEMBL14032206 |
| DB12423 |
| [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl(2-decoxy-3-dodecylsulfanylpropyl)hydrogen phosphate |
| CHEMBL3989603 |
| 1-(3-azido-5-o-{[2-(decyloxy)-3-(dodecylsulfanyl)propoxy](hydroxy)phosphoryl}-2,3-dideoxypentofuranosyl)-4-hydroxy-5-methylpyrimidin-2(1h)-one |
| DTXSID10931199 |
| Q1440263 |
| CS-0107327 |
| HY-126781 |
| AKOS040748377 |
Fozivudine tidoxil (FZD) is a thioether lipid-zidovudine (ZDV) conjugate with anti-HIV activity demonstrated in vitro and in pilot phase I studies.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Fozivudine tidoxil (FZD) is a thioether lipid-zidovudine (ZDV) conjugate with anti-HIV activity demonstrated in vitro and in pilot phase I studies. " | ( Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. Anderson, R; Boerner, D; Diquet, B; Girard, PM; Pegram, PS; Raffi, F; Sereni, D; Tubiana, R, 2000) | 2.02 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In each dosage group (200 mg daily, 400 mg daily, 200 mg twice daily, 800 mg daily, 400 mg twice daily, and 600 mg twice daily), 12 patients were randomized to receive in a 10:2 ratio either FZD or a placebo for 4 weeks." | ( Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. Anderson, R; Boerner, D; Diquet, B; Girard, PM; Pegram, PS; Raffi, F; Sereni, D; Tubiana, R, 2000) | 0.58 |
| "At the dosage used in this study, treatment with FZD results in a short-term decrease in viral load with no adverse effects." | ( Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection. Campbell, B; Fogle, JE; Sumner, D; Tompkins, MB; Tompkins, WA, ) | 1.57 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (62.50%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (25.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||